Современные подходы к терапии ожирения у детей: что нового?

Abstract

Objective of the Review: To analyse scientific publications in non-drug and drug therapy of paediatric obesity. Key Points. The paramount challenge in obesity management is timely diagnosis of overweight by paediatricians and prompt initiation of efficient non-drug therapy. A tremendous advantage of the life style, nutrition and physical activity correction is their safety. Psychologist engagement boosts non-drug therapy efficiency. Where non-drug therapy is inefficient, medications can be prescribed to children over 12 years old in addition to lifestyle correction. Orlistat possesses an acceptable efficiency profile and is safe, but it is associated with a number of adverse reactions and does not modify the eating habits of the patient. Liraglutide, a glucagon-like peptide product, has proven to be efficient in adolescents of 12 to 18 years old, including visceral adiposopathy management. An extended action with minor adverse enteric reactions makes Liraglutide a promising product for the management of adolescent obesity. Conclusion. Obesity management in children and adolescents is based on a set of non-drug measures possessing proven efficiency and safety. In Russia, Orlistat and Liraglutide are approved for the use in children. Metformin can be considered as an off-label medication. To prove the efficiency and safety of bariatric surgery, further studies are warranted. Keywords: obesity, children, non-drug therapy, drug therapy, Liraglutide.